“…Thus, the net benefit of BCG therapy is preservation of the bladder in 88% of patients. Similar results were reported by others with different strains of BCG [3–8]. The T1G3 recurrences after BCG were treated with either a second course of BCG in a few or radical cystectomy in most patients.…”
Section: Discussionsupporting
confidence: 85%
“…Historically, early cystectomy for T1G3 tumours had yielded good results but currently the emphasis is on bladder preservation. Various authors have reported success and failure in the management of T1G3 tumours using various strains of intravesical BCG in an adjuvant setting [3–23]. We herein report our experience of managing 69 patients with T1G3 bladder tumours using endovesical BCG (Danish 1331 strain).…”
This series further confirms the benefits of intravesical BCG (Danish 1331) in an adjuvant setting; furthermore, this treatment facilitates bladder preservation by reducing recurrences and delaying the progression in many patients.
“…Thus, the net benefit of BCG therapy is preservation of the bladder in 88% of patients. Similar results were reported by others with different strains of BCG [3–8]. The T1G3 recurrences after BCG were treated with either a second course of BCG in a few or radical cystectomy in most patients.…”
Section: Discussionsupporting
confidence: 85%
“…Historically, early cystectomy for T1G3 tumours had yielded good results but currently the emphasis is on bladder preservation. Various authors have reported success and failure in the management of T1G3 tumours using various strains of intravesical BCG in an adjuvant setting [3–23]. We herein report our experience of managing 69 patients with T1G3 bladder tumours using endovesical BCG (Danish 1331 strain).…”
This series further confirms the benefits of intravesical BCG (Danish 1331) in an adjuvant setting; furthermore, this treatment facilitates bladder preservation by reducing recurrences and delaying the progression in many patients.
“…Boccon-Gibod et al followed 47 T1 patients, who received BCG treatment between one or three sessions for 14 to 60 months. In BCG group, they found 36% recurrence and 21% progression risk, whereas in the control group, there was 90% recurrence and 34% progression risk [12]. Pansadoro et al reported a study which they applied at least 6 weeks of BCG treatment to 50 patients with high grade T1 disease.…”
Elmer This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.